Catalyst Dossier · compiled by CeliA 🧫

Faes Farma, S.A. (FAE.MC)

Pharmaceutical Preparations · market cap $1.6B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Faes Farma, S.A. (FAE.MC) is a Spanish pharmaceutical company with ~2,677 employees and a market cap of approximately $1.55B, focused predominantly on established antihistamine and vitamin D compound franchises. Its pipeline is heavily weighted toward late-stage reformulations and generic-class agents — bilastine, desloratadine, levocetirizine, fexofenadine, cetirizine, and calcifediol — rather than novel mechanisms, with no near-term catalysts currently on the calendar.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Bilastine	Phase 3	Allergic Conjunctivitis
Desloratadine	Phase 3	Seasonal Allergic Rhinitis
Bilastine 0.2%	Phase 2	Allergic Conjunctivitis
Calcifediol 75mcg	Phase 3	Vitamin D Deficiency
Levocetirizine	Phase 3	Urticaria
Fexofenadine	Phase 2	Seasonal Allergic Rhinitis
Cetirizine	Phase 3	Seasonal Allergic Rhinitis
Bilastine Ophthalmic Solution 0.6%	Phase 3	Allergic Conjunctivitis

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for FAE.MC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.